Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial

Besselink, Marc GH, van Santvoort, Hjalmar C, Buskens, Erik, Boermeester, Marja A, van Goor, Harry, Timmerman, Harro M, Nieuwenhuijs, Vincent B, Bollen, Thomas L, van Ramshorst, Bert, Witteman, Ben JM, Rosman, Camiel, Ploeg, Rutger J, Brink, Menno A, Schaapherder, Alexander FM, Dejong, Cornelis HC, Wahab, Peter J, van Laarhoven, Cees JHM, van der Harst, Erwin, van Eijck, Casper HJ, Cuesta, Miguel A, Akkermans, Louis MA, Gooszen, Hein G · 2008 · The Lancet

Abstract

BACKGROUND Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral administration of probiotics could prevent infectious complications, but convincing evidence is scarce. Our aim was to assess the effects of probiotic prophylaxis in patients with predicted severe acute pancreatitis. METHODS In this multicentre randomised, double-blind, placebo-controlled trial, 298 patients with predicted severe acute pancreatitis (Acute Physiology and Chronic Health Evaluation [APACHE II] score > or =8, Imrie score > or =3, or C-reactive protein >150 mg/L) were randomly assigned within 72 h of onset of symptoms to receive a multispecies probiotic preparation (n=153) or placebo (n=145), administered enterally twice daily for 28 days. The primary endpoint was the composite of infectious complications--ie, infected pancreatic necrosis, bacteraemia, pneumonia, urosepsis, or infected ascites--during admission and 90-day follow-up. Analyses were by intention to treat. This study is registered, number ISRCTN38327949. FINDINGS One person in each group was excluded from analyses because of incorrect diagnoses of pancreatitis; thus, 152 individuals in the probiotics group and 144 in the placebo group were analysed. Groups were much the same at baseline in terms of patients' characteristics and disease severity. Infectious complications occurred in 46 (30%) patients in the probiotics group and 41 (28%) of those in the placebo group (relative risk 1.06, 95% CI 0.75-1.51). 24 (16%) patients in the probiotics group died, compared with nine (6%) in the placebo group (relative risk 2.53, 95% CI 1.22-5.25). Nine patients in the probiotics group developed bowel ischaemia (eight with fatal outcome), compared with none in the placebo group (p=0.004). INTERPRETATION In patients with predicted severe acute pancreatitis, probiotic prophylaxis with this combination of probiotic strains did not reduce the risk of infectious complications and was associated with an increased risk of mortality. Probiotic prophylaxis should therefore not be administered in this category of patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(08)60207-x

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 43 references

Cited by

See all 1,367

Metadata

Authors
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., Rosman, C., Ploeg, R. J., Brink, M. A., Schaapherder, A. F., Dejong, C. H., Wahab, P. J., van Laarhoven, C. J., van der Harst, E., van Eijck, C. H., Cuesta, M. A., Akkermans, L. M., & Gooszen, H. G.
Affiliations
  • University Medical Center Utrecht (NL)
  • University Medical Center Groningen (NL)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • St. Antonius Ziekenhuis (NL)
  • Ziekenhuis Gelderse Vallei (NL)
  • Canisius-Wilhelmina Ziekenhuis (NL)
  • Meander Medisch Centrum (NL)
  • Leiden University Medical Center (NL)
  • Maastricht University Medical Centre (NL)
  • Rijnstate Hospital (NL)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Corresponding author
Gooszen, Hein G
Venue
The Lancet
Publisher
Elsevier BV
Published
2008-02
Volume
371
Issue
9613
Pages
651-659
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2126413585
Cited by
1,367
References
43
Citations by year
2026: 52 · 2025: 53 · 2024: 57 · 2023: 71 · 2022: 54 · 2021: 57 · 2020: 66 · 2019: 73 · 2018: 57 · 2017: 51 · 2016: 60 · 2015: 83 · 2014: 91 · 2013: 83 · 2012: 106
FWCI
123.64
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Keywords
probiotics, acute pancreatitis, severe acute pancreatitis, infectious complications, probiotic prophylaxis, infected pancreatic necrosis, bacteremia, mortality, intestinal ischemia, enteral administration, APACHE II score, C-reactive protein
MeSH terms
Acute Disease, Adult, Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Netherlands, Pancreatitis, Placebos, Logistic Models, Treatment Outcome, Statistics, Nonparametric, Probiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(08)60207-x
The paper
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., Rosman, C., Ploeg, R. J., Brink, M. A., Schaapherder, A. F., Dejong, C. H., Wahab, P. J., van Laarhoven, C. J., van der Harst, E., van Eijck, C. H., . . . Gooszen, H. G. (2008). Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(08)60207-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.